Why is ETaR considered a challenging target for antibody discovery?

ETaR is a seven-transmembrane GPCR that readily loses its native conformation upon membrane extraction, complicating antigen preparation and binder selection. Creative Biolabs overcomes this with Nanodisc reconstitution, VLP display, and cell-based panning to preserve natural epitopes throughout the campaign.

What is the difference between an antagonistic and an agonistic anti-ETaR antibody?

An antagonistic antibody blocks ET-1 binding and silences vasoconstrictive signaling, making it suited for diseases like PAH. An agonistic antibody mimics ET-1 and activates the receptor, useful for probing receptor biology or therapeutic stimulation. We support both formats with tailored screening cascades.

Can Creative Biolabs discover antibodies that distinguish ETaR from ETbR?

Yes. Using subtractive selection or epitope masking, we enrich antibodies specific to ETaR without cross-reacting with the highly homologous ETbR subtype, enabling clear functional dissection and safer therapeutic profiles.

What is the typical timeline for an anti-ETaR antibody discovery project?

Lead identification typically takes three to six months, depending on the chosen library and screening strategy. Contact us for a detailed, project-specific timeline assessment.

Does Creative Biolabs provide antibodies suitable for in vivo studies?

Yes. Our antibodies can be engineered with Fc modifications to extend half-life, reduce immunogenicity, or tailor effector functions. All candidates are characterized for stability and functionality before delivery to ensure reliable in vivo performance.

Anti-ETaR Antibody Introduction

Overview Background Applications Workflow FAQs

Overview of Anti-ETaR Antibody

Endothelin Receptor Type A, commonly referred to as ETaR, is a member of the G protein-coupled receptor (GPCR) superfamily encoded by the EDNRA gene. Its primary endogenous ligand is Endothelin 1 (ET-1), a potent vasoactive peptide. Upon ET-1 binding, ETaR couples predominantly to the Gq/11 protein and activates the phospholipase C pathway, generating inositol trisphosphate and diacylglycerol. This cascade mobilizes intracellular calcium and drives sustained vasoconstriction in vascular smooth muscle cells. Beyond its canonical cardiovascular role, ETaR signaling is deeply implicated in the pathogenesis of pulmonary arterial hypertension (PAH), systemic sclerosis (SSc), renal fibrotic disorders and several malignancies. These clinical associations position ETaR as a high value therapeutic node. Anti-ETaR antibodies offer a targeted intervention strategy with distinct advantages over small molecule antagonists, including superior receptor subtype specificity, prolonged pharmacokinetic profiles and an absence of the hepatotoxic liabilities observed with some endothelin receptor blockers. Creative Biolabs is dedicated to advancing anti-ETaR antibody discovery by providing fully integrated research services that bridge target analysis, antibody generation and functional characterization. Our platform supports both antagonistic and agonistic modalities, encompassing custom agonistic antibody design and agonistic antibody therapy development tailored to your research goals.

Background on ETaR from Physiology to Disease

Under homeostatic conditions, ETaR is expressed predominantly on vascular smooth muscle cells and cardiomyocytes, where it balances ETbR mediated vasodilation to regulate vascular tone. This equilibrium is disrupted in multiple disease states. In pulmonary arterial hypertension, elevated ET-1 drives unchecked vasoconstriction and vascular remodeling. Anti-ETaR antibodies that block ET-1 binding can lower pulmonary vascular resistance and improve right heart function. Notably, circulating anti-ETaR autoantibodies in SSc associated PAH patients correlate with disease severity and prognosis, serving as both predictive biomarkers and pathogenic drivers. In systemic sclerosis, anti-ETaR and anti-AT1R autoantibodies contribute to endothelial injury, fibroblast activation and progressive organ scarring. Antibody mediated ETaR blockade can disrupt this pathological loop.

In the kidney, metabolic stressors upregulate ET-1, and ETaR activation drives efferent arteriole constriction, leading to hyperfiltration, podocyte damage, and proteinuria, all of which can be blunted by antagonist antibodies. In oncology, the ET-1/ETaR axis promotes tumor proliferation, angiogenesis and metastasis, and its blockade sensitizes tumors to monoclonal antibody therapies. These interconnected pathologies underscore the urgent need for high quality, functionally validated anti-ETaR antibodies, a need that Creative Biolabs translates into actionable discovery campaigns.

Research Applications of Anti-ETaR Antibodies

Well characterized anti-ETaR antibodies are versatile tools that accelerate multiple research and translational programs. Creative Biolabs supports every application stage from early discovery to preclinical development.

Functional Studies

Anti-ETaR antibodies can serve as selective agonists or antagonists to dissect receptor signaling in specific cell types or tissue contexts. We offer customized development of functional antibodies with user defined modes of action, including partial agonism or allosteric modulation.

Disease Model Validation

In rodent PAH models, renal fibrosis models and tumor xenograft systems, anti-ETaR antibodies help validate the pathogenic contribution of the ET-1/ETaR axis and quantify therapeutic efficacy. Our antibodies are engineered with the appropriate Fc format to match your in vivo study requirements.

Diagnostic Biomarker Development

The detection of anti-ETaR autoantibodies in patient sera is emerging as a valuable diagnostic and prognostic tool in SSc and PAH. We can generate reference grade anti-ETaR antibodies for use in ELISA or bead based assays that standardize autoantibody measurement across clinical cohorts.

Drug Discovery and Development

Lead anti-ETaR antibodies identified through our platforms are readily adaptable to advanced therapeutic modalities, including antibody drug conjugates (ADCs), bispecific antibodies and CAR T cell constructs. We provide full developability assessment to prepare your candidates for transition into downstream development.

Structural Biology Support

High affinity, conformationally selective anti-ETaR antibodies can act as crystallization chaperones or cryo EM fiducials, enabling high resolution structural studies of this challenging receptor. Our stabilization focused selection schemes deliver antibodies ideally suited for structural biology.

Partner with Our Scientists to Transform Your Research Challenges

Technical Workflow Overview

Fig.1 Antibody Development Strategy Meeting. (Creative Biolabs AI)

Creative Biolabs delivers a comprehensive suite of services purpose built for GPCR antibody discovery, with ETaR as a fully supported flagship target. Our offering spans the entire workflow from immunogen design to lead validation.

1. Antigen Preparation Services

We construct ETaR overexpressing cell lines, perform membrane protein extraction, reconstitute the receptor into Nanodiscs or VLPs, and design mRNA based immunization strategies. Every antigen format is quality controlled for native epitope presentation.

2. Phage Display Library Construction

We build high diversity, fully human synthetic antibody libraries, immune libraries or naïve libraries that are tailored to your ETaR targeting needs. Each library undergoes stringent quality assessment for diversity and display efficiency.

3. Phage Display Screening Services

Our screening modalities include solid phase panning, solution phase panning, cell based selection and subtractive selection to eliminate cross reactive binders against ETbR or other related receptors. We employ automated platforms for throughput and reproducibility.

4. Monoclonal Antibody Discovery

We isolate therapeutic grade monoclonal antibodies using optimized antibody frameworks. Following primary screening, selected clones proceed to recombinant expression and purification for detailed characterization.

5. Antibody Engineering

Lead candidates can be humanized, affinity matured via yeast display or light chain shuffling, and optimized for stability and solubility. We evaluate aggregation propensity, thermal stability and expression yield early to flag developability risks.

6. Functional Characterization Services

Our validation cascade includes ELISA, flow cytometry, surface plasmon resonance (SPR) and cell based functional assays. We measure receptor antagonism, agonism and signaling bias to deliver a comprehensive binding and activity profile.

Advance Your Anti-ETaR Project on Our Professional Platform

FAQs

Q: Why is ETaR considered a challenging target for antibody discovery?
A: ETaR is a seven-transmembrane GPCR that readily loses its native conformation upon membrane extraction, complicating antigen preparation and binder selection. Creative Biolabs overcomes this with Nanodisc reconstitution, VLP display, and cell-based panning to preserve natural epitopes throughout the campaign.
Q: What is the difference between an antagonistic and an agonistic anti-ETaR antibody?
A: An antagonistic antibody blocks ET-1 binding and silences vasoconstrictive signaling, making it suited for diseases like PAH. An agonistic antibody mimics ET-1 and activates the receptor, useful for probing receptor biology or therapeutic stimulation. We support both formats with tailored screening cascades.
Q: Can Creative Biolabs discover antibodies that distinguish ETaR from ETbR?
A: Yes. Using subtractive selection or epitope masking, we enrich antibodies specific to ETaR without cross-reacting with the highly homologous ETbR subtype, enabling clear functional dissection and safer therapeutic profiles.
Q: What is the typical timeline for an anti-ETaR antibody discovery project?
A: Lead identification typically takes three to six months, depending on the chosen library and screening strategy. Contact us for a detailed, project-specific timeline assessment.
Q: Does Creative Biolabs provide antibodies suitable for in vivo studies?
A: Yes. Our antibodies can be engineered with Fc modifications to extend half-life, reduce immunogenicity, or tailor effector functions. All candidates are characterized for stability and functionality before delivery to ensure reliable in vivo performance.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: